Vericel

Vericel Corporation
Formerly	Aastrom Biosciences, Inc.
Type	Public
Traded as	NASDAQ: VCEL; Russell 2000 Component
Industry	Biotechnology
Founded	1989 in Ann Arbor, Michigan, United States
Headquarters	Cambridge, Massachusetts, United States
Number of locations	2
Key people	Nick Colangelo (CEO); Daniel Orlando (COO); Gerard Michel (CFO);
Products	MACI; Epicel; Carticel;

Vericel Corporation is a public, American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.^[1]

In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011.^[1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.^[1]

In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.^[1]

References

1 2 3 4 Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[seiffert2014-1] 1 2 3 4 Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.